Synergistic and attenuated research method and device for treating oral lichen planus by using hydroxychloroquine and application
Through network pharmacology and molecular docking technology, the targets and adverse reaction targets of hydroxychloroquine were screened, and combined with glycyrrhizin as a combination drug, the toxicity problem of hydroxychloroquine in the treatment of oral lichen planus was solved, and the treatment effect was improved and safe were achieved. Improvement of sexuality.
Patent Information
- Application Number
- CN202411024533.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-29
AI Technical Summary
When hydroxychloroquine is used to treat oral lichen planus, there are off-target effects and adverse reactions, such as ocular toxicity, cardiotoxicity, hematological toxicity and hepatotoxicity, and the molecular targets and related mechanisms of its therapeutic response are unclear, which limits the therapeutic effect and Security.
Through network pharmacology and molecular docking technology, the potential therapeutic targets and adverse reaction targets of hydroxychloroquine are screened, and the binding ability of candidate combination drugs to these targets is verified, and the combination drugs such as glycyrrhizone can be administered in combination with hydroxychloroquine. , preferentially occupy adverse reaction targets, alleviate toxic reactions and enhance the therapeutic effect.
The effect of hydroxychloroquine in treating oral lichen planus has been achieved, reducing the risk of adverse reactions, and providing a theoretical basis for combined treatment and drug development direction.
Smart Images

Figure CN118969064A_ABST
Abstract
Description
Technical Field
[0001] The embodiments of the present invention relate to the field of biomedical technology, and in particular to a research method, device and application of enhancing the efficacy and reducing the toxicity of hydroxychloroquine in treating oral lichen planus. Background Art
[0002] Oral lichen planus (OLP) is a common chronic inflammatory disease of the oral mucosa in clinical practice. It often presents as bilateral symmetrical lesions with various morphologies and the potential for malignant transformation. In particular, patients with erosive oral lichen planus (EOLP), characterized by large-area single or multifocal erosions, face a higher risk of malignant transformation and recurrence. At the same time, long-term pain significantly reduces the quality of life, which brings a heavy psychological burden to patients. In clinical practice, systemic glucocorticoids are recommended as the first-line treatment for severe EOLP. However, its use is often limited by contraindications, serious adverse reactions, and resistance to treatment. Domestic and international guidelines for the diagnosis and treatment of oral lichen planus suggest that hydroxychloroquine (HCQ) can be used as an alternative therapy in this case. HCQ can be used as an off-label drug to treat OLP and has shown effectiveness in multiple studies. However, the interaction of HCQ with targets outside the expected therapeutic effect can cause off-target effects and adverse reactions, including ocular toxicity, cardiac toxicity, hematological toxicity, and hepatotoxicity. If specific molecular targets can be identified, it may help promote therapeutic effects and guide future drug development. However, the molecular targets and related mechanisms of HCQ inducing its therapeutic response in OLP are still unclear. Summary of the invention
[0003] The embodiments of the present invention provide a method, device and application for studying the synergistic and toxicity-reducing effect of hydroxychloroquine in treating oral lichen planus. By exploring key targets and adverse reaction targets and verifying the combined drugs, the combined drugs with a detoxifying effect on hydroxychloroquine in treating oral lichen planus are studied, providing a theoretical basis for the combined treatment of oral lichen planus.
[0004] In an embodiment of the present invention, a first aspect provides a method for studying the efficacies and toxicity reduction of hydroxychloroquine in treating oral lichen planus, the method comprising:
[0005] Network pharmacology and molecular docking techniques were used to screen potential therapeutic targets of hydroxychloroquine in the treatment of oral lichen planus;
[0006] Use the GEO database and clinical samples to verify the expression levels of the potential therapeutic targets and identify the key targets of hydroxychloroquine in the treatment of oral lichen planus;
[0007] Identify potential adverse effect targets shared by diseases associated with hydroxychloroquine toxicity, including drug-induced liver injury, retinopathy, cardiomyopathy, and leukopenia;
[0008] Identify common targets between hydroxychloroquine and candidate combination drugs;
[0009] In the case where the common target includes the adverse reaction target, determining the binding energy of the candidate combination drug to the key target and the adverse reaction target based on molecular docking technology;
[0010] When the binding ability of the candidate combination drug to the adverse reaction target is better than that of hydroxychloroquine, and the binding to the key target does not affect the binding of hydroxychloroquine to the key target; it is determined that when hydroxychloroquine and the candidate combination drug are administered in combination, the candidate combination drug preferentially occupies the adverse reaction target to exert a synergistic therapeutic effect and a toxicity reduction effect.
[0011] Optionally, network pharmacology and molecular docking techniques were used to screen potential therapeutic targets of hydroxychloroquine in the treatment of oral lichen planus, including:
[0012] Conduct network pharmacology analysis to identify multiple target genes as potential targets;
[0013] Molecular docking is performed on hydroxychloroquine and the multiple potential targets to determine the main interaction modes between the multiple potential targets and hydroxychloroquine, and multiple potential targets with strong binding abilities are selected as potential therapeutic targets.
[0014] Optionally, the GEO database and clinical samples are used to verify the expression levels of the potential therapeutic targets, and key targets for hydroxychloroquine in treating oral lichen planus are determined, including:
[0015] Use GEO public data to verify RNA expression levels of potential therapeutic targets;
[0016] Clinical samples were used to verify the protein expression levels of potential therapeutic targets and to identify the key targets of hydroxychloroquine in the treatment of oral lichen planus.
[0017] Optionally, the GEO database and clinical samples are used to verify the expression levels of the potential therapeutic targets, and key targets for hydroxychloroquine in treating oral lichen planus are determined, including:
[0018] NOK cells stimulated with LPS were used as an in vitro model to simulate oral lichen planus epithelial cells;
[0019] NOK cells were treated with hydroxychloroquine to simulate clinical treatment response, the mRNA expression levels of the potential therapeutic targets before and after hydroxychloroquine treatment were determined, and the key targets of hydroxychloroquine in treating oral lichen planus were determined.
[0020] In an embodiment of the present invention, a second aspect provides a research device for enhancing the efficacy and reducing the toxicity of hydroxychloroquine in treating oral lichen planus, the device comprising:
[0021] Potential therapeutic target identification module, used to screen potential therapeutic targets of hydroxychloroquine in the treatment of oral lichen planus using network pharmacology and molecular docking technology;
[0022] A key target determination module, which is used to verify the expression level of the potential therapeutic target using the GEO database and clinical samples, and to determine the key target of hydroxychloroquine in the treatment of oral lichen planus;
[0023] Potential adverse reaction target identification module, which is used to identify potential adverse reaction targets common to diseases associated with hydroxychloroquine toxicity, including drug-induced liver injury, retinopathy, cardiomyopathy, and leukopenia;
[0024] Common target identification module, used to identify common targets between hydroxychloroquine and candidate combination drugs;
[0025] An analysis module, for determining the binding energy of the candidate combination drug to the key target and the adverse reaction target based on molecular docking technology when the common target includes the adverse reaction target;
[0026] A determination module is used to determine that when hydroxychloroquine and the candidate combination drug are co-administered, the candidate combination drug preferentially occupies the adverse reaction target to exert a synergistic therapeutic effect and a toxicity reduction effect, when the binding energy of the candidate combination drug to the adverse reaction target is better than that of hydroxychloroquine, and the binding to the key target does not affect the binding of hydroxychloroquine to the key target.
[0027] Optionally, the potential therapeutic target determination module is used to:
[0028] Conduct network pharmacology analysis to identify multiple target genes as potential targets;
[0029] Molecular docking is performed on hydroxychloroquine and the multiple potential targets to determine the main interaction modes between the multiple potential targets and hydroxychloroquine, and multiple potential targets with strong binding abilities are selected as potential therapeutic targets.
[0030] Optionally, the key target determination module is used to:
[0031] Use GEO public data to verify RNA expression levels of potential therapeutic targets;
[0032] Clinical samples were used to verify the protein expression levels of potential therapeutic targets and to identify the key targets of hydroxychloroquine in the treatment of oral lichen planus.
[0033] Optionally, the key target determination module is used to:
[0034] NOK cells stimulated with LPS were used as an in vitro model to simulate oral lichen planus epithelial cells;
[0035] NOK cells were treated with hydroxychloroquine to simulate clinical treatment response, and the mRNA expression levels of the potential therapeutic targets before and after hydroxychloroquine treatment were determined to determine the key targets of hydroxychloroquine in treating oral lichen planus.
[0036] In an embodiment of the present invention, a third aspect provides the combined use of hydroxychloroquine and glycyrrhizin in the preparation of a medicament for treating oral lichen planus, wherein the key targets of hydroxychloroquine in treating oral lichen planus are HSP90α and HSP90β, and the hydroxychloroquine is used as an HSP90α agonist and an HSP90β agonist to treat oral lichen planus. In the process of treating oral lichen planus, the adverse reaction target of hydroxychloroquine is HSP90α, and the glycyrrhizin detoxifies hydroxychloroquine by occupying the binding site of HSP90α.
[0037] Glycyrrhizin and hydroxychloroquine bind to different sites on the same residue of HSP90β, and glycyrrhizin does not affect the binding of hydroxychloroquine to HSP90β.
[0038] In an embodiment of the present invention, the key targets of hydroxychloroquine for treating oral lichen planus can be determined based on network pharmacology and molecular docking technology combined with the GEO database and clinical samples, and the potential adverse reaction targets of hydroxychloroquine can be determined based on the potential adverse reaction targets shared in diseases related to the toxic reaction of hydroxychloroquine, and the common targets of the candidate combination drug and hydroxychloroquine are further determined. When the common targets include adverse reaction targets and the binding ability of the candidate combination drug to the adverse reaction target is better than that of hydroxychloroquine, it is determined that the candidate combination drug can exert a synergistic therapeutic effect and a toxicity reduction effect with hydroxychloroquine.
[0039] In the embodiments of the present invention, by exploring the key therapeutic targets of hydroxychloroquine, potential adverse reaction targets, and common targets between hydroxychloroquine and candidate combination drugs, the efficacy of hydroxychloroquine is determined from a pharmacological perspective, and combination drugs that can exert synergistic therapeutic effects and toxicity reduction effects are sought. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments of the present invention will be briefly introduced below. Obviously, the accompanying drawings in the following description are only some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative work.
[0041] Figure 1 It is a flow chart of the steps of the research method for enhancing the efficacy and reducing the toxicity of hydroxychloroquine in treating oral lichen planus provided by an embodiment of the present invention;
[0042] Figure 2It is a schematic diagram of molecular target screening and molecular docking related to the treatment of oral lichen planus by hydroxychloroquine provided in an embodiment of the present invention;
[0043] Figure 3 It is a schematic diagram of expression data of potential targets of hydroxychloroquine for treating oral lichen planus in a GEO data set provided by an embodiment of the present invention;
[0044] Figure 4 It is a schematic diagram of the expression verification of potential targets of hydroxychloroquine in treating oral lichen planus in clinical samples provided by an embodiment of the present invention;
[0045] Figure 5 It is a schematic diagram of in vitro efficacy verification of hydroxychloroquine in treating oral lichen planus provided by an embodiment of the present invention;
[0046] Figure 6 It is a schematic diagram of potential targets of hydroxychloroquine toxicity reaction and its detoxification effect provided by an embodiment of the present invention. DETAILED DESCRIPTION
[0047] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.
[0048] Specifically, Figure 1 As shown, it shows a flow chart of the steps of the research method for enhancing the efficacy and reducing the toxicity of hydroxychloroquine in treating oral lichen planus provided in an embodiment of the present invention, and the method comprises the following steps:
[0049] S101, screening potential therapeutic targets of hydroxychloroquine in the treatment of oral lichen planus using network pharmacology and molecular docking techniques;
[0050] S102, using the GEO database and clinical samples to verify the expression level of the potential therapeutic target and determine the key target of hydroxychloroquine in the treatment of oral lichen planus;
[0051] S103, Identify potential adverse effect targets shared by diseases associated with hydroxychloroquine toxicity, including drug-induced liver injury, retinopathy, cardiomyopathy, and leukopenia;
[0052] S104, identification of common targets between hydroxychloroquine and candidate combination drugs;
[0053] S105, when the common target includes the adverse reaction target, determining the binding energy of the candidate combination drug to the key target and the adverse reaction target based on molecular docking technology;
[0054] S106, when the binding ability of the candidate combination drug to the adverse reaction target is better than that of hydroxychloroquine, and the binding to the key target does not affect the binding of hydroxychloroquine to the key target; it is determined that when hydroxychloroquine and the candidate combination drug are administered in combination, the candidate combination drug preferentially occupies the adverse reaction target to exert a synergistic therapeutic effect and toxicity reduction effect.
[0055] In the present embodiment, the present embodiment proposes to use computational analysis, histological evaluation and in vitro studies to determine the key targets of HCQ in the treatment of oral lichen planus.
[0056] In the embodiments of the present invention, network pharmacology and molecular docking were used to screen the potential therapeutic targets of HCQ in the treatment of OLP.
[0057] Specifically, in an optional implementation manner, based on the above embodiment, step S101 includes the following sub-steps:
[0058] S1011, network pharmacology analysis was performed to identify multiple target genes as potential targets;
[0059] S1012, performing molecular docking of hydroxychloroquine with the multiple potential targets, determining the main interaction modes between the multiple potential targets and hydroxychloroquine, and selecting multiple potential targets with strong binding abilities as potential therapeutic targets.
[0060] Figure 2 The schematic diagram of molecular target screening and molecular docking related to hydroxychloroquine in the treatment of oral lichen planus is shown, where (A) represents the chemical structure of hydroxychloroquine, (B) represents the screening of potential target genes for OLP, (C) represents the intersection Venn diagram of hydroxychloroquine and potential target genes for OLP, (D) represents the stepwise screening of the top 20 target genes before the PPI network, and (E) represents the molecular docking visualization diagram of hydroxychloroquine and potential targets including HSP90β, HSP90α, EGFR and VCP. The blue bars represent hydroxychloroquine; the red bars represent the amino acid residues of the binding site; the yellow dotted lines represent the hydrogen bonds and distances of the binding site.
[0061] In the present embodiment, network pharmacology analysis was first performed to select 20 target genes as potential targets (such as Figure 2 Then, molecular docking was performed between HCQ and these 20 candidate targets. The main interaction mode between the candidate targets and HCQ was hydrogen bonding, among which HSP90AB1 showed the strongest binding ability (as shown in Figure 2A). Figure 2 (shown in (E)).
[0062] In the embodiment of the present invention, based on pharmacological analysis and molecular docking technology, HSP90β, HSP90α, EGFR and VCP are screened as potential therapeutic targets, and the expression levels of the potential therapeutic targets are further verified using the GEO database and clinical samples to determine the key targets of hydroxychloroquine in treating oral lichen planus. Specifically, in an optional embodiment, based on the above embodiment, S102 includes the following sub-steps:
[0063] S1021, using GEO public data to verify RNA expression levels of potential therapeutic targets;
[0064] S1022, using clinical samples to verify the protein expression levels of potential therapeutic targets and determine the key targets of hydroxychloroquine in the treatment of oral lichen planus;
[0065] S1023, NOK cells stimulated with LPS were used as an in vitro model to simulate oral lichen planus epithelial cells;
[0066] S1024, treating NOK cells with hydroxychloroquine to simulate clinical treatment response, determining the mRNA expression levels of the potential therapeutic targets before and after hydroxychloroquine treatment, and determining the key targets of hydroxychloroquine in treating oral lichen planus.
[0067] In the present embodiment, the GEO database and clinical samples were used to verify the expression level of potential targets. Specifically, the GEO datasets GSE38616, GSE52130 and GSE213346 related to OLP were used.
[0068] Figure 3 A schematic diagram showing the changes in expression levels of potential targets for HCQ treatment of OLP in the GEO database.
[0069] Among them, (A) represents the differentially expressed genes in the three OLP datasets, (B) represents the calculation of the expression levels of the top 20 candidate targets in the three datasets and the drawing of representative heat maps (GSE52130), and (C) represents that among the 20 candidate targets, the expression of HSP90AB1, HSP90AA1, EGFR and VCP is significantly different (fold change ≥ 1.5; P < 0.1)).
[0070] In the present embodiment, the heat map shows the differential expression of the top 20 targets screened in the GSE52130 dataset (eg Figure 3 The expression of HSP90AB1, HSP90AA1, EGFR, and VCP in the three databases showed statistically significant differences (P<0.1, as shown in Figure 2A). Figure 3 (as shown in (C)).
[0071] In the examples of the present invention, paraffin-embedded sections of normal mucosal tissue and oral lichen planus tissue were obtained from the clinic for hematoxylin-eosin (H&E), immunohistochemistry (IHC) and four-color multiple immunohistochemistry (mIHC) staining.
[0072] Figure 4 The schematic diagram of the expression verification of potential targets in clinical samples is shown. (A) represents representative H&E staining of human samples including normal oral mucosal tissue (n=10) and oral precancerous lesion (OLP) tissue (n=18), (B) represents representative IHC images and statistical analysis of HSP90β, HSP90α, EFGR and VCP (scale bar, 100μm), (C) represents representative mIHC staining images of OLP and normal tissue sections (DAPI, PAN-CK, HSP90β and HSP90α). In the same field of view, there is a certain co-localization phenomenon between HSP90β and HSP90α proteins, but the expression distribution of HSP90β is more extensive (scale bar, 50μm). All data are expressed as mean ± standard error.
[0073] In the present invention, it was observed that the expression of HSP90β in the spinous layer and basal layer of OLP epithelium was significantly reduced (eg Figure 4 Similarly, the expression of HSP90α in OLP tissues was significantly decreased in the epithelial spinous layer and basal layer. There was no significant difference in the expression of EGFR or VCP between the two groups (as shown in Figure 4 Subsequently, mIHC showed that HSP90β was localized in the cytoplasm in both the normal and OLP groups, while HSP90α was translocated from the nucleus of the normal group to the cytoplasm of the OLP group (as shown in Figure 4 The above findings revealed that the expression of HSP90α and HSP90β was significantly downregulated in OLP epithelium, indicating that they may be the key targets of HCQ in the treatment of OLP.
[0074] In the present embodiment, in order to further verify the therapeutic effect of HCQ on OLP, a human normal oral keratinocyte (NOK) cell line was obtained from the State Key Laboratory of Oral Diseases. NOK cells were treated with lipopolysaccharide (LPS, Sigma-Aldrich, L2880, 10 μg / ml) or HCQ (MCE, HY-B1370) to stimulate NOK to simulate the clinical treatment response of OLP epithelium or HCQ. Cell proliferation was assessed using immunofluorescence (IF) staining of Ki67. NOK cells were stained with PI / RNase A (9:1) solution, and cell cycle changes were assessed by flow cytometry. Total RNA was extracted for qRT-PCR detection.
[0075] Figure 5The schematic diagram of the in vitro efficacy verification of hydroxychloroquine (HCQ) is shown. Among them, (A) represents Ki67 immunofluorescence staining (scale bar, 100 μm) after NOK cells were treated with LPS and different concentrations of HCQ, (B) represents representative images of flow cytometry analysis of cell cycle and histograms of cell numbers in G1, S and G2 phases using PI staining, (C) represents qRT-PCR analysis of mRNA expression levels of inflammatory cytokines TNF-α and IL6 after NOK cells were treated with LPS and 10 μM HCQ for 24 hours, (D) represents qRT-PCR analysis of mRNA expression levels of HSP90AB1 and HSP90AA1 after NOK cells were treated with LPS and 10 μM HCQ for 24 hours.
[0076] like Figure 5 As shown, it was observed that HCQ treatment at different concentrations significantly increased the proliferation of LPS-treated NOK cells, which was confirmed by increased Ki67 expression (Fig. Figure 5 24 hours after treatment, 10 μM HCQ alleviated the LPS-induced S phase arrest of NOK cells and significantly reduced the expression of typical inflammatory cytokines, including TNF-α and IL6 (as shown in Figure 2A). Figure 5 Mechanistically, the RNA levels of HSP90α / β (representing HSP90AA1 and HSP90AB1, respectively) were downregulated after LPS stimulation (as shown in (B)-(C)). Figure 5 This is consistent with the IHC findings (as shown in (D) Figure 5 HCQ treatment significantly restored the levels of HSP90AA1 and HSP90AB1, especially the increase of HSP90AB1 was particularly significant (as shown in Figure 2B). Figure 5 In vitro studies showed that HCQ stimulated cell proliferation of OLP-mimicking epithelial cells and inhibited the secretion of TNF-α and IL6, accompanied by enhanced HSP90α / β expression. These findings suggest that HCQ may exert its therapeutic effects on OLP through HSP90α and HSP90β.
[0077] Therefore, in the embodiments of the present invention, it is determined that the key targets of hydroxychloroquine in treating oral lichen planus are HSP90α and HSP90β.
[0078] In the examples of the present invention, it is proposed that the interaction of HCQ with targets other than its expected therapeutic effect may cause off-target effects and adverse reactions, including ocular toxicity, cardiac toxicity, hematotoxicity and hepatotoxicity. Based on this, it is proposed in the examples of the present invention to determine the potential adverse reaction targets shared by hydroxychloroquine in drug-induced liver injury, retinopathy, cardiomyopathy and leukopenia.
[0079] In an optional embodiment, based on the above embodiment, step S104 includes: screening the potential therapeutic targets of the candidate combination drugs in the treatment of oral lichen planus through network pharmacology, and based on this, determining the common targets between hydroxychloroquine and the candidate combination drugs.
[0080] In the embodiments of the present invention, by exploring the key therapeutic targets of hydroxychloroquine, potential adverse reaction targets, and common targets between hydroxychloroquine and candidate combination drugs, the efficacy of hydroxychloroquine is determined from a pharmacological perspective, and combination drugs that can exert synergistic therapeutic effects and toxicity reduction effects are sought.
[0081] In the embodiments of the present invention, when the common target between hydroxychloroquine and the candidate combination drug includes an adverse reaction target and the binding ability of the candidate combination drug to the adverse reaction target is better than that of hydroxychloroquine, it indicates that the candidate combination drug can preferentially bind to the adverse reaction target, so that hydroxychloroquine cannot bind to the adverse reaction target, thereby eliminating the adverse reactions that may be caused, and does not affect the binding of hydroxychloroquine to the key treatment target and does not affect its therapeutic effect.
[0082] In the embodiment of the present invention, the steps S103 to S108 are described by taking glycyrrhizin (GL) as an example of the candidate drug for combination use: Specifically, Figure 6 The schematic diagram of the potential targets of HCQ's toxicity and detoxification is shown. Among them, (A) shows the schematic diagram of licorice and the intersection of GL target genes and the top 20 genes in the PPI network of HCQ. (B) shows the molecular docking mode diagram of HCQ and GL with HSP90β and HSP90α. Blue sticks, HCQ or GL; red sticks, amino acid residues at the binding site; yellow dotted lines, hydrogen bonds and distances at the binding site. The bottom indicates the molecular docking binding energy, (C) shows the gene set involved in the toxicity of HCQ, and (D) shows an overview of HCQ and GL in the treatment of OLP through HSP90α / β.
[0083] In the present invention, six common targets were found between HCQ and GL, namely HSP90AA1, HSP90AB1, CDK2, EGFR, ESR1 and HSPA8 (eg Figure 6 In addition, GL has a better binding ability to HSP90α / β than HCQ, as shown in the molecular docking results (as shown in Figure 6(B)). However, the binding effect of GL on HSP90α or HSP90β is different from that of HCQ. GL and HCQ bind to different sites on the same residue of HSP90β, which means that GL may not affect the binding of HCQ to HSP90β. In contrast, the residue site at which GL binds to HSP90α is the same as that of HCQ. In step S103, eight targets (such as Figure 6 (C)). HSP90α is involved, indicating that HSP90α is a potential target for HCQ-induced toxicity. HSP90α is identified as a common potential adverse reaction target in diseases associated with hydroxychloroquine toxicity.
[0084] These observations suggest that HSP90α may serve as an effective target for glycyrrhizin to antagonize HCQ toxicity. Given these observations, it is hypothesized that when HCQ and glycyrrhizin are co-administered, glycyrrhizin preferentially occupies the HSP90α residue binding site without affecting the interaction between HCQ and HSP90β, thereby exerting a synergistic therapeutic and detoxifying effect (e.g. Figure 6 (D)
[0085] In the examples of the present invention, HSP90α and HSP90β were innovatively identified as potential targets for HCQ treatment of OLP. HSP90α and HSP90β belong to the HSP90 protein family, are abundant in normal cells, and are common housekeeping proteins. Nuclear HSP90α is essential for maintaining genomic stability, while cytoplasmic HSP90 has been observed to redistribute to the cell membrane in various cancer cells. In the examples of the present invention, it was observed that the expression of HSP90α and HSP90β in epithelial cells of OLP patients was reduced compared with the control group, and the cytoplasmic translocation of HSP90α was increased. The examples of the present invention found that HSP90α and HSP90β are closely related to the pathogenesis of OLP and have the potential to be used as therapeutic targets.
[0086] HSP90α and HSP90β share similar structures and functions, directing the normal folding, intracellular disposition, and proteolytic turnover of many key regulators of cell growth and survival. For example, HSP90α and HSP90β can affect cell proliferation by controlling the TGFβ signaling cascade and modulate inflammation through multiple signaling pathways, such as NF-κB, TLR4, and JAK / STAT. In particular, keratinocytes from patients with OLP produce 10–20-fold higher levels of IL6 and TNF-α than normal mucosa. HSP90 has also been found to play a regulatory role in IL6 / TNF-α in mouse models of plaque psoriasis and irritant dermatitis. In confirming the therapeutic effect of HCQ on OLP, we observed that HCQ exhibited pro-proliferative and anti-inflammatory effects in vitro. The strong binding of HCQ to HSP90AB1 and HSP90AA1, as well as the upregulation of RNA expression after HCQ exposure, collectively suggest that HCQ has a restorative effect on HSP90α / β. These findings reveal that HCQ may exert its therapeutic effect on OLP by restoring HSP90α / β levels to inhibit the production of IL6 and TNF-α and promote the recovery of epithelial cells.
[0087] Although previous studies have not explored the detailed differences between HSP90α and HSP90β in depth, some evidence suggests that HSP90 subtypes exhibit tissue-specific expression patterns and different functions under pathological conditions. In the present invention, HSP90α was identified as a potential target involved in adverse reactions of HCQ, which is consistent with the results of other studies that found that HSP90α is associated with hepatotoxicity, ocular toxicity, and cardiac toxicity. In addition, reducing serum HSP90α levels in mouse models can improve fatty hepatitis; HSP90α plays a vital role in rod cell survival, and long-term inhibition leads to harmful degradation of specific photoreceptor proteins such as PDE6 and GRK1; HSP90α is also considered to be the best core hub protein drug target for HCQ-related QT interval prolongation, and the potassium channel hERG, which is critical for cardiac repolarization, only interacts with HSP90α but not HSP90β. These findings indirectly support our conclusion that HSP90α is a potential target for toxic reactions associated with HCQ treatment of OLP.
[0088] Due to the recognized anti-inflammatory and hepatoprotective effects of GL, it is often used in combination with HCQ for the treatment of OLP. Its anti-inflammatory effect is similar to that of hydrocortisone, and its hepatoprotective mechanism involves anti-steatosis, anti-oxidative stress and immunomodulatory effects. In view of this, the combined use of HCQ and GL is also considered to be a reasonable method for treating COVID-19 or inflammatory skin diseases. The embodiments of the present invention reveal that both HCQ and GL target HSP90α and HSP90β. GL may show a greater preference for binding to residue sites of HSP90α than HCQ. This molecular discovery may contribute to the synergistic and detoxifying effects of the combined use of GL and HCQ. This discovery is of great significance for optimizing the use of HCQ in the treatment of viral infections, skin diseases and OLP.
[0089] In the examples of the present invention, the study demonstrated the efficacy of HCQ in the treatment of OLP. Mechanistically, HCQ may exert its therapeutic effect as an agonist of HSP90α / β. In addition, GL can reduce the toxicity of HCQ by occupying the HSP90α binding site. These findings provide evidence-based medicine and theoretical basis for the optimal clinical application of HCQ in the treatment of OLP.
[0090] In an embodiment of the present invention, a device for studying the efficacies and toxicity reduction of hydroxychloroquine in treating oral lichen planus is also provided, and the device comprises:
[0091] Potential therapeutic target identification module, used to screen potential therapeutic targets of hydroxychloroquine in the treatment of oral lichen planus using network pharmacology and molecular docking technology;
[0092] A key target determination module, which is used to verify the expression level of the potential therapeutic target using the GEO database and clinical samples, and to determine the key target of hydroxychloroquine in the treatment of oral lichen planus;
[0093] Potential adverse reaction target identification module, which is used to identify potential adverse reaction targets common to diseases associated with hydroxychloroquine toxicity, including drug-induced liver injury, retinopathy, cardiomyopathy, and leukopenia;
[0094] Common target identification module, used to identify common targets between hydroxychloroquine and candidate combination drugs;
[0095] An analysis module, for determining the binding energy of the candidate combination drug to the key target and the adverse reaction target based on molecular docking technology when the common target includes the adverse reaction target;
[0096] A determination module is used to determine that when hydroxychloroquine and the candidate combination drug are administered together, the candidate combination drug preferentially occupies the adverse reaction target to exert a synergistic therapeutic effect and a toxicity reduction effect, when the binding ability of the candidate combination drug to the adverse reaction target is better than that of hydroxychloroquine, and the binding to the key target does not affect the binding of hydroxychloroquine to the key target.
[0097] Optionally, the potential therapeutic target determination module is used to:
[0098] Conduct network pharmacology analysis to identify multiple target genes as potential targets;
[0099] Molecular docking is performed on hydroxychloroquine and the multiple potential targets to determine the main interaction modes between the multiple potential targets and hydroxychloroquine, and multiple potential targets with strong binding abilities are selected as potential therapeutic targets.
[0100] Optionally, the key target determination module is used to:
[0101] Use GEO public data to verify RNA expression levels of potential therapeutic targets;
[0102] Clinical samples were used to verify the protein expression levels of potential therapeutic targets and to identify the key targets of hydroxychloroquine in the treatment of oral lichen planus.
[0103] Optionally, the key target determination module is used to:
[0104] NOK cells stimulated with LPS were used as an in vitro model to simulate oral lichen planus epithelial cells;
[0105] NOK cells were treated with hydroxychloroquine to simulate clinical treatment response, and the mRNA expression levels of the potential therapeutic targets before and after hydroxychloroquine treatment were determined to determine the key targets of hydroxychloroquine in treating oral lichen planus.
[0106] Glycyrrhizin and hydroxychloroquine bind to different sites on the same residue of HSP90β, and glycyrrhizin does not affect the binding of hydroxychloroquine to HSP90β.
[0107] In an embodiment of the present invention, based on the above research, a combined use of hydroxychloroquine and glycyrrhizin in the preparation of a drug for treating oral lichen planus is proposed. The key targets of hydroxychloroquine in treating oral lichen planus are HSP90α and HSP90β. The hydroxychloroquine is used as an HSP90α agonist and an HSP90β agonist to treat oral lichen planus. In the process of treating oral lichen planus, the adverse reaction target of hydroxychloroquine is HSP90α, and the glycyrrhizin detoxifies hydroxychloroquine by occupying the binding site of HSP90α.
[0108] Glycyrrhizin and hydroxychloroquine bind to different sites on the same residue of HSP90β, and glycyrrhizin does not affect the binding of hydroxychloroquine to HSP90β.
[0109] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.
[0110] Although the preferred embodiments of the present invention have been described, those skilled in the art may make additional changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the embodiments of the present invention.
[0111] Finally, it should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or terminal device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or terminal device. In the absence of further restrictions, the elements defined by the sentence "comprise a ..." do not exclude the existence of other identical elements in the process, method, article or terminal device including the elements.
[0112] The above is a detailed introduction to the synergistic and toxicity-reducing research method, device and application of hydroxychloroquine for treating oral lichen planus provided by the present invention. Specific examples are used herein to illustrate the principles and implementation methods of the present invention. The description of the above embodiments is only used to help understand the method of the present invention and its core idea; at the same time, for those skilled in the art, according to the idea of the present invention, there will be changes in the specific implementation methods and application scopes. In summary, the content of this specification should not be understood as limiting the present invention.
Claims
1. Research methods for enhancing the efficacy and reducing the toxicity of hydroxychloroquine in the treatment of oral lichen planus. It is characterized in that The method comprises: Network pharmacology and molecular docking techniques were used to screen potential therapeutic targets of hydroxychloroquine in the treatment of oral lichen planus; Use the GEO database and clinical samples to verify the expression levels of the potential therapeutic targets and identify the key targets of hydroxychloroquine in the treatment of oral lichen planus; Identify potential adverse effect targets shared by diseases associated with hydroxychloroquine toxicity, including drug-induced liver injury, retinopathy, cardiomyopathy, and leukopenia; Identify common targets between hydroxychloroquine and candidate combination drugs; In the case where the common target includes the adverse reaction target, determining the binding energy of the candidate combination drug to the key target and the adverse reaction target based on molecular docking technology; When the binding ability of the candidate combination drug to the adverse reaction target is better than that of hydroxychloroquine, and the binding to the key target does not affect the binding of hydroxychloroquine to the key target; it is determined that when hydroxychloroquine and the candidate combination drug are administered in combination, the candidate combination drug preferentially occupies the adverse reaction target to exert a synergistic therapeutic effect and a toxicity reduction effect.
2. The research method for enhancing the efficacy and reducing the toxicity of hydroxychloroquine in treating oral lichen planus according to claim 1, It is characterized in that Network pharmacology and molecular docking techniques were used to screen potential therapeutic targets of hydroxychloroquine in the treatment of oral lichen planus, including: Conduct network pharmacology analysis to identify multiple target genes as potential targets; Molecular docking is performed on hydroxychloroquine and the multiple potential targets to determine the main interaction modes between the multiple potential targets and hydroxychloroquine, and multiple potential targets with strong binding abilities are selected as potential therapeutic targets.
3. The research method for enhancing the efficacy and reducing the toxicity of hydroxychloroquine in treating oral lichen planus according to claim 1, It is characterized in that The GEO database, clinical samples, and in vitro cell experiments were used to verify the expression levels of the potential therapeutic targets and identify the key targets of hydroxychloroquine in the treatment of oral lichen planus, including: Use GEO public data to verify RNA expression levels of potential therapeutic targets; Clinical samples were used to verify the protein expression levels of potential therapeutic targets and to identify the key targets of hydroxychloroquine in the treatment of oral lichen planus.
4. The research method for enhancing the efficacy and reducing the toxicity of hydroxychloroquine in treating oral lichen planus according to claim 1, It is characterized in that The GEO database, clinical samples, and in vitro cell experiments were used to verify the expression levels of the potential therapeutic targets and identify the key targets of hydroxychloroquine in the treatment of oral lichen planus, including: NOK cells stimulated with LPS were used as an in vitro model to simulate oral lichen planus epithelial cells; NOK cells were treated with hydroxychloroquine to simulate clinical treatment response, the mRNA expression levels of the potential therapeutic targets before and after hydroxychloroquine treatment were determined, and the key targets of hydroxychloroquine in treating oral lichen planus were determined.
5. Research device for enhancing the efficacy and reducing the toxicity of hydroxychloroquine in the treatment of oral lichen planus, It is characterized in that The device comprises: Potential therapeutic target identification module, used to screen potential therapeutic targets of hydroxychloroquine in the treatment of oral lichen planus using network pharmacology and molecular docking technology; A key target determination module, which is used to verify the expression level of the potential therapeutic target using the GEO database and clinical samples, and to determine the key target of hydroxychloroquine in the treatment of oral lichen planus; Potential adverse reaction target identification module, which is used to identify potential adverse reaction targets common to diseases associated with hydroxychloroquine toxicity, including drug-induced liver injury, retinopathy, cardiomyopathy, and leukopenia; Common target identification module, used to identify common targets between hydroxychloroquine and candidate combination drugs; An analysis module, for determining the binding energy of the candidate combination drug to the key target and the adverse reaction target based on molecular docking technology when the common target includes the adverse reaction target; A determination module is used to determine that when hydroxychloroquine and the candidate combination drug are administered together, the candidate combination drug preferentially occupies the adverse reaction target to exert a synergistic therapeutic effect and a toxicity reduction effect, when the binding ability of the candidate combination drug to the adverse reaction target is better than that of hydroxychloroquine, and the binding to the key target does not affect the binding of hydroxychloroquine to the key target.
6. The synergistic and toxicity-reducing research device for treating oral lichen planus with hydroxychloroquine according to claim 5, It is characterized in that The potential therapeutic target determination module is used to: Conduct network pharmacology analysis to identify multiple target genes as potential targets; Molecular docking is performed on hydroxychloroquine and the multiple potential targets to determine the main interaction modes between the multiple potential targets and hydroxychloroquine, and multiple potential targets with strong binding abilities are selected as potential therapeutic targets.
7. The synergistic and toxicity-enhancing research device for treating oral lichen planus with hydroxychloroquine according to claim 5, It is characterized in that The key target determination module is used to: Use GEO public data to verify RNA expression levels of potential therapeutic targets; Clinical samples were used to verify the protein expression levels of potential therapeutic targets and to identify the key targets of hydroxychloroquine in the treatment of oral lichen planus.
8. The synergistic and toxicity-reducing research device for treating oral lichen planus with hydroxychloroquine according to claim 5, It is characterized in that The key target determination module is used to: NOK cells stimulated with LPS were used as an in vitro model to simulate oral lichen planus epithelial cells; NOK cells were treated with hydroxychloroquine to simulate clinical treatment response, and the mRNA expression levels of the potential therapeutic targets before and after hydroxychloroquine treatment were determined to determine the key targets of hydroxychloroquine in treating oral lichen planus.
9. The combined use of hydroxychloroquine and glycyrrhizin in the preparation of a medicament for treating oral lichen planus, It is characterized in that The key targets of hydroxychloroquine in treating oral lichen planus are HSP90α and HSP90β. The hydroxychloroquine is used as an HSP90α agonist and an HSP90β agonist to treat oral lichen planus. In the process of treating oral lichen planus, the adverse reaction target of hydroxychloroquine is HSP90α. The glycyrrhizic acid detoxifies hydroxychloroquine by occupying the binding site of HSP90α.
10. The combined use of hydroxychloroquine and glycyrrhizin according to claim 9 in the preparation of a medicament for treating oral lichen planus, It is characterized in that Glycyrrhizin and hydroxychloroquine bind to different sites on the same residue of HSP90β, and glycyrrhizin does not affect the binding of hydroxychloroquine to HSP90β.
Citation Information
Patent Citations
Application of hydroxychloroquine, combined medicine containing hydroxychloroquine and application of combined medicine
CN116687927A
Method for predicting HLA-binding peptides using protein structural features
US20210104294A1
